Spin-off company of the Masaryk University
Institute of Biostatistics and Analyses Ltd (IBA) is a spin-off company of the Masaryk University, with a share of ownership by the Masaryk University.
The company focuses mainly on the areas of project management of clinical research, real-world evidence (RWE) projects, organisation and management of clinical trials, particularly non-interventional clinical trials and health registries. This main activity is complemented with other services such as market access support, cost-effectiveness analysis, pharmacovigilance, analysis of clinical data, development of tailored software products and graphic design.
About us
On 28–29 June 2017, software developers and testers from the CLADE-IS-stars team held a hackathon focused on the processing of a series of user stories related to data management in clinical trials.
Our company provides technological and analytical background for clinical registries of the Czech Society for Oncology, which have been established for the monitoring of effectiveness and safety of targeted cancer therapy. Similarly to previous years, data analyses of these registries were used as a background for a series of articles published in international medical journals.
We are seeking a new colleague for the position PHP programmer – Symfony developer.
Quality management
Pharmacovigilance
Web studio
Real-world evidence/data
The Institute of Biostatistics and Analyses is an investigator of the project “Extending services portfolio of an information system for the data management in clinical research”. The project is supported by the OP EIC from the European Union funds.
Main objective of the project is the development of a platform for composition of information systems focused on data management and data mining in the field of pharmaceutical industry and life sciences. Offer of digital services based on a developed and validated information system will make reliable analytical models accessible to the companies for their decision-making and precise information sources for regulatory bodies. The project steps out of a laboratory environment of clinical trials and focuses on the evidence supported by real-world data.
